Antoni Vilaseca Cabo, MD, discusses the rationale behind the phase 1 study evaluating the safety and efficacy of TAR-210 in ...

Shubham Pant, MD, MBBS, discussed the use of zanidatamab and the HERIZON-BTC-01 trial in HER2-positive biliary tract cancer ...

Joe DePinto, MBA, discusses some of the key challenges to equitable access to cell and gene therapies, especially in ...

A phase 1 trial of α-lactalbumin vaccine for the treatment of patients with triple-negative breast cancer demonstrated safety ...

Along with the Oncology Brothers, Paolo Tarantino, MD, provides an overview of the pPhase 3 EMERALD study, which evaluates the efficacy of elacestrant as a second-line treatment for ER+/HER2–- ...

Santhosh K. Sadashiv, MD, discusses the role of chimeric antigen receptor T-cell therapy in patients with multiple myeloma.

Panelist discusses how the future treatment landscape for EGFR-mutant advanced non–small cell lung cancer is evolving to address current unmet needs and offers clinical pearls to community oncologists ...

In an interview, Antoni Vilaseca Cabo, MD, discussed the clinical activity of TAR-210 in patients with non-muscle invasive ...

Invikafusp alfa showed promise as a treatment option across a range of high tumor mutational burden cancers or virally ...

Along with the Oncology Brothers, Paolo Tarantino, MD, discusses how ESR1 mutations (ESR1m) are commonly observed in HR+ breast cancer, particularly after prolonged endocrine therapy, and emphasizes ...

Ibrahim N. Muhsen, MD, evaluated the efficacy of brexu-cel in adult patients with central nervous system involvement in relapsed/refractory B-cell acute lymphoblastic leukemia.

Denise Yardley, MD, discussed results with ribociclib in patients with early-stage breast cancer with no lymph node ...